The National Institute for Health Care Excellence has recommended Amgen's Kyprolis, or carfilzomib, for the treatment of relapsed multiple myeloma in patients who have not received Janssen's Velcade, or bortezomib. Progression-free survival averaged 18.7 months in study participants taking both Kyprolis and dexamethasone, compared with 9.4 months in patients taking Velcade and dexamethasone.
NICE recommends new combo therapy for first multiple myeloma relapse
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.